Document Detail

New strategies to manage complicated pleural effusions.
Jump to Full Text
MedLine Citation:
PMID:  22621656     Owner:  NLM     Status:  Publisher    
EXPANDED ABSTRACT: CITATION: Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, Bentley A, Kahan BC, Wrightson JM, Davies HE, Hooper CE, Lee YC, Hedley EL, Crosthwaite N, Choo L, Helm EJ, Gleeson FV, Nunn AJ, Davies RJ: N Engl J Med 2011, 365:518-26. PMID: 21830966, available on www.pubmed. gov BACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is the key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial therapy (Multicenter Intrapleural Sepsis Trial [MIST1]). METHODS: Objective: To evaluate the efficacy and safety of intrapleural DNase alone, alteplase alone, or the combination of both, to improve pleural drainage.Design: Multicenter, double-blind, double-dummy, 2 × 2 factorial randomized trial.Setting: Eleven centers in the United Kingdom (UK).Subjects: Adult patients (mean age 59 years, 72% men), who had clinical evidence of infection, and pleural fluid that had macroscopic purulence, a positive culture or Gram stain for bacteria, or a pH < 7.2.Intervention: Patients were assigned to 1 of the 4 study interventions for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNase, t-PA and placebo, or DNase and placebo.Outcomes: The primary outcome was the change in pleural opacity, measured as the percentage of the hemithorax occupied by effusion, on chest radiography on day 7 as compared with day 1. Secondary outcomes included referral for surgery, duration of hospital stay, and adverse events. RESULTS: The mean (± SD) change in pleural opacity was greater in the t-PA-DNase group than in the placebo group (-29.5 ± 23.3% vs. -17.2 ± 19.6%; difference, -7.9%; 95% confidence interval [CI], -13.4 to -2.4; P = 0.005). The change observed with t-PA alone and with DNase alone (-17.2 ± 24.3 and -14.7 ± 16.4%, respectively) was not significantly different from that observed with placebo. The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% CI, 0.03 to 0.87; P = 0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 to 9.75; P = 0.01). Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% CI, -12.0 to -1.9; P = 0.006). Hospital stay with either agent alone was not significantly different from that with placebo. The frequency of adverse events did not differ significantly among the groups. CONCLUSIONS: Intrapleural t-PA-DNase therapy improved fluid drainage in patients with pleural infection and reduced the frequency of surgical referral and the duration of hospital stay. Treatment with DNase alone or t-PA alone was ineffective.
Majed Safiyeh; David Huang
Related Documents :
11767426 - Gastric fluid ph and volume in gynaecologic out-patients. influences of cimetidine and ...
10908256 - Double blind randomised placebo controlled trial of adjunctive prednisolone in the trea...
2115186 - A double blind placebo controlled trial of intravenous prostacyclin (pgi2) in 108 patie...
3777596 - Cimetidine treatment of recalcitrant acute allergic urticaria.
22240886 - An rct on the effects of topical cgp on surgical wound appearance and residual scarring...
15807826 - Effect of mitomycin c on ciliary body and intraocular pressure with various application...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-22
Journal Detail:
Title:  Critical care (London, England)     Volume:  16     ISSN:  1466-609X     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9801902     Medline TA:  Crit Care     Country:  -    
Other Details:
Languages:  ENG     Pagination:  312     Citation Subset:  -    
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Crit Care
Journal ID (iso-abbrev): Crit Care
ISSN: 1364-8535
ISSN: 1466-609X
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2012 BioMed Central Ltd
Print publication date: Year: 2012
Electronic publication date: Day: 22 Month: 5 Year: 2012
pmc-release publication date: Day: 22 Month: 5 Year: 2013
Volume: 16 Issue: 3
First Page: 312 Last Page: 312
PubMed Id: 22621656
ID: 3580622
Publisher Id: cc11337
DOI: 10.1186/cc11337

New strategies to manage complicated pleural effusions
Majed Safiyeh12 Email:
David Huang123 Email:
1Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
2The Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh, Pittsburgh, PA
3Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA


More than 65,000 cases of pleural infection occur in the United States and United Kingdom each year [1], and the incidence is increasing in both children and adults [2]. Both community and hospital acquired bacterial pneumonia are complicated by pleural infections [3]. Despite the advances in therapeutic strategies, pleural infections are associated with high mortality rates of 10-20% [4].

There are several classifications of pleural effusions based on evolution (exudative, fibrinoproliferative with evidence of loculation, and formation of fibrous peel) and fluid characteristics (clear, viscous, or pus). Drainage alone is usually adequate for an uncomplicated effusion. However, drainage is often insufficient for patients with pleural infection who have a complicated effusion with increased viscosity and loculation [5]. The standard management of pleural infections consists of antibiotics and draining the infected pleural fluid [6]. However, more than 30% of patients fail standard therapy and require surgical referral. These patients incur a longer duration of hospital stay of 12-15 days and increased utilization of healthcare resources [4].

Observational data suggest that using fibrinolytic drugs in the intrapleural space can decrease the failure rate, reduce surgical referral, and improve chest tube drainage by cleaving intrapleural fibrinous septations [7,8]. This theory was tested by many randomized controlled trials using different fibrinolytics, but failed to improve clinically meaningful end points [9]. Most notably, the 454 patients in the Multicenter Intrapleural Sepsis Trial (MIST1) showed no benefit from intrapleural streptokinase. However, the absence of benefit was felt possibly due to the presence of free extracellular deoxyribonucleic acid (DNA) and other bacterial components in the pleural space, which increase fluid viscosity and hinder fibrinolysis [8]. Adding DNase to cleave the free DNA may reduce fluid viscosity and permit pleural clearance by fibrinolytic drugs [10].

To test this hypothesis, the second multicenter trial (MIST2) by Rahman and colleagues was conducted at 11 centers in the UK. In this randomized trial, the authors used a different intrapleural fibrinolytic agent (t-PA rather than streptokinase) and added DNase for cleavage of free DNA. The authors conducted a standard factorial study analysis and found a significant interaction between t-PA and DNase with regard to the primary outcome. They therefore compared each of the three intervention groups to placebo.

The t-PA-DNase combination was significantly superior to placebo and each drug alone in improving the changes in opacity on chest x-ray on day 7 vs. day 1 (primary end point), decreasing the number of surgical referrals at 3 and 12 months (4% vs. 14%), and decreasing the days of hospitalizations by 6.7 days. However, monotherapy with either t-PA or DNase showed no benefit when compared to placebo, and DNase alone resulted in an increase in surgical referrals and hospitalization days compared to placebo.

Strengths of this trial include: a well-defined study protocol, multicenter, randomized, double-blind, double-dummy design, and complete follow-up. There are a few limitations. First, although only 3 serious adverse events with pulmonary bleeding (intrapleural hemorrhage, hemoptysis) occurred, all three were in the t-PA-DNase group (n = 52). Future use of this drug combination should carefully monitor for pulmonary bleeding. Second, the primary end point was the absolute change in chest x-ray opacity. However, the trial was powered to detect a slightly different endpoint, the proportion of patients who had a 50% relative reduction in opacity. Never-theless, the overall results were striking, with only one patient in the t-PA-DNase arm not achieving any opacification reduction, compared to several patients in the other arms. Additionally, there was reduction in the number of surgical referrals, a patient-centered endpoint.


Rahman and colleagues should be commended for demonstrating that dual intrapleural therapy with t-PA and DNase in patients with pleural infection improved changes in opacity on chest x-ray and reduced need for surgical intervention and hospital stay. Although larger trials are needed to replicate these results, dual intrapleural therapy may be a useful option, especially for patients who are high-risk for surgery.

Competing interests

The authors declare that they have no competing interests.

Light RW,Girard WM,Jenkinson SG,George RB,Parapneumonic effusionsAm J MedYear: 19806950751210.1016/0002-9343(80)90460-X7424940
Ahmed AE,Yacoub TE,Empyema thoracisClin Med Insights Circ Respir Pulm MedYear: 201041821157522
Davies CW,Kearney SE,Gleeson FV,Davies RJ,Predictors of outcome and long-term survival in patients with pleural infectionAm J Respir Crit Care MedYear: 19991601682168710556140
Farjah F,Symons RG,Krishnadasan B,Wood DE,Flum DR,Management of pleural space infections: a population-based analysisJ Thorac Cardiovasc SurgYear: 200713334635110.1016/j.jtcvs.2006.09.03817258562
Kroegel C,Antony VB,Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapyEur Respir JYear: 1997102411241810.1183/09031936.97.101024119387973
Davies CW,Gleeson FV,Davies RJ,BTS guidelines for the management of pleural infectionThoraxYear: 200358Suppl 2ii182812728147
Misthos P,Sepsas E,Konstantinou M,Athanassiadi K,Skottis I,Lioulias A,Early use of intrapleural fibrinolytics in the management of postpneumonic empyema:a prospective studyEur J Cardiothorac SurgYear: 20052859960310.1016/j.ejcts.2005.07.00516129614
Simpson G,Roomes D,Heron M,Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pusChestYear: 20001171728173310.1378/chest.117.6.172810858409
Tokuda Y,Matsushima D,Stein GH,Miyagi S,Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysisChestYear: 200612978379010.1378/chest.129.3.78316537882
Heffner JE,Multicenter trials of treatment for empyema -- after all these yearsN Engl J MedYear: 2005352926810.1056/NEJMe04835215745984

Article Categories:
  • Journal Club Critique

Previous Document:  Direct Nanomechanical Measurement of an Anchoring Transition in a Nematic Liquid Crystal Subject to ...
Next Document:  Transformation of 1H-benzotriazole by Ozone in Aqueous Solution.